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Abstract
Background: Molecular switch systems that activate gene expression by a small molecule are effective
technologies that are widely used in applied biological research. Nuclear receptors are valuable candidates for
these regulation systems due to their functional role as ligand activated transcription factors. Previously, our group
engineered a variant of the retinoid × receptor to be responsive to the synthetic compound, LG335, but not
responsive to its natural ligand, 9-cis-retinoic acid.
Results: This work focuses on characterizing a molecular switch system that quantitatively controls transgene
expression. This system is composed of an orthogonal ligand/nuclear receptor pair, LG335 and GRQCIMFI, along
with an artificial promoter controlling expression of a target transgene. GRQCIMFI is composed of the fusion of the
DNA binding domain of the yeast transcription factor, Gal4, and a retinoid × receptor variant. The variant consists
of the following mutations: Q275C, I310M, and F313I in the ligand binding domain. When introduced into
mammalian cell culture, the switch shows luciferase activity at concentrations as low as 100 nM of LG335 with a
6.3 ± 1.7-fold induction ratio. The developed one-component system activates transgene expression when
introduced transiently or virally.
Conclusions: We have successfully shown that this system can induce tightly controlled transgene expression and
can be used for transient transfections or retroviral transductions in mammalian cell culture. Further
characterization is needed for gene therapy applications.
Background
Gene regulation systems are important research tools
for studying gene function and can provide numerous
benefits for clinical applications. Several systems have
been designed that place a target transgene under the
control of an engineered transcription factor that is acti-
vated in the presence of an exogenous ligand [1]. These
systems have been successfully used to control expres-
sion of a target transgene in a cellular environment with
high expression levels in response to an extensive range
of ligand concentrations [2]. To date, several research
groups have used these systems to control transgene
expression in both cell culture as well as animal models.
Some of the most commonly used examples include the
progesterone receptor (PR)/mifepristone (RU486)
inducible system [3], the tetracycline inducible system
[4], and the ecdysone-responsive regulation system [5].
The progesterone receptor (PR) inducible system, also
known as GeneSwitch®, regulates gene expression using
low concentrations of RU486 that binds to a chimeric
regulator composed of a truncated PR fused to a Gal4
DNA binding domain and p65, the activation domain
[3,6-8]. Upon the addition of RU486, the regulator then
binds a DNA sequence composed of six Gal4 response
elements (RE) and activates gene expression. One disad-
vantage of this system is that the ligand, RU486, has
been shown to interfere with other biological pathways
(at a much higher concentration of ligand), so long term
usage could have extensive side effects [9]. In the tetra-
cycline (Tet) inducible system, the prokaryotic protein,
Tet, binds to a specific DNA sequence called tetO in
response to tetracycline or doxycycline (dox) [4]. This
system can function as both an ON-switch as well as an
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OFF-switch [10]. The ligand dox is inexpensive and
“bioavailable” [11]. Since this system utilizes bacterial
proteins, an immunogenic response may occur if used
in human gene therapy [12,13]. Finally, the ecdysone-
responsive regulation system (also known as RheoS-
witch®) is based on a heterodimer between the insect
steroid hormone receptor, ecdysone receptor (EcR), and
the retinoid × receptor (RXR) [14]. Despite low basal
expression and high fold induction [15,16], this system
requires the over expression of two transgenes (EcR and
RXR) simultaneously, complicating viral delivery or a
single component system. Another disadvantage would
be that over expression of RXR poses a safety concern
as RXR is involved in many metabolic pathways [17].
The concerns posed by these systems permit the devel-
opment of new or improved molecular switch systems.
According to Toniatti and co-workers, there are sev-
eral criteria for an effective molecular switch system.
First, the switch should be an “ON-switch”, meaning the
switch should be able to be turned on and off based on
the addition or removal of drug. Second, the drug and
the molecular switch should be target specific and not
interfere with endogenous metabolic pathways. Third,
target gene expression should correlate with the dose of
the ligand, which should rapidly reverse protein expres-
sion upon removal of ligand. Finally, the system should
have low basal activity, be inactive in the absence of the
ligand but strongly stimulated by ligand administration,
hence high fold induction levels [18]. This paper charac-
terizes a molecular switch system based on an orthogo-
nal ligand/receptor pair that attempts to fulfill most of
these requirements.
Nuclear receptors (NR) have the natural ability to bind
ligands and regulate transcription. When a small mole-
cule binds to a NR, a conformational change occurs in
the receptor’s structure allowing recruitment of the
transcription machinery. This role in transcription
makes NR crucial for the induction of gene expression
and regulating a variety of cellular processes such as
proliferation, differentiation, intracellular signalling,
reproduction, and metabolism [19,20]. The modularity
of nuclear receptors makes them attractive candidates
for molecular switch systems; the ability for NR domains
to function independently of each other allows them to
be fused to other proteins for various protein engineer-
ing applications.
When engineering NR, the DNA binding domain
(DBD) of these receptors can be engineered to recognize
an artificial promoter containing multimeric-binding
sites and a minimal promoter [1,2,21]. The ligand bind-
ing domain (LBD) can also be mutated to bind a syn-
thetic small molecule that can reversibly regulate
expression of genes. In addition to binding the synthetic
ligand, NR can also be modified to eliminate their ability
to bind their natural ligand. Several cases have shown
the pairing of an unnatural or synthetic ligand with a
mutant transcription factor [22]. In these systems, the
small molecule binds to the mutant receptor and acti-
vates expression of a target transgene. These ligand/
receptor pairs are ideal for molecular switch systems
because of their selectivity and lack of interaction in
other cellular pathways.
Previously, RXR was engineered to be regulated by
LG335, a synthetic inactive analog of the compound
LGD1069 (also known as bexarotene, trade name Tar-
gretin®) [23,24]. RXR belongs to the class of retinoid
receptors [25], and plays important roles in cellular
morphogenesis and differentiation [26,27]. Structurally,
RXR contains a ligand binding domain (LBD) that
recognizes various endogenous small lipophilic com-
pounds such as 9-cis-retinoic acid (9cRA), and a DBD
that recognizes a DNA sequence called RXR response
elements (RE) [28]. When residues in the RXR LBD
were mutated, one RXR variant Q275C, I310M, F313I
(QCIMFI) had reverse ligand specificity, activating with
LG335 but not with the wild type (wt) ligand, 9cRA
[29]. This RXR variant can be further engineered to
behave as a molecular switch and control gene expres-
sion in cell culture. This work focuses on the characteri-
zation of this molecular switch system in a two-
component system and then this system is combined
into a one-component system for stable expression in
cell culture.
Results
Characterization of the two-component molecular switch
system
The molecular switch system was designed to contain
an engineered NR, a promoter region, and a target
transgene. Previously, Doyle et al. showed that a RXR
variant consisting of three mutations in the LBD,
Q275C, I310M, F313I (QCIMFI), and a unchanged DBD
activated transcription in response to LG335 but not by
the RXR natural ligand, 9cRA [29]. For determining the
luciferase activation profile of this variant, a reporter
plasmid containing the CRBPII response element con-
trolling expression of the luciferase gene (pLuc_CRBPII)
is used [28]. QCIMFI is activated in response to LG335
at concentrations as low as 100 nM (EC50 value is 38
nM) with a 14.5 ± 1.6-fold induction and no activation
with 9cRA (Figure 1A). Conversely, RXRwt is activated
by 1 μM 9cRA (EC50 value is 597 nM) with a 13.4 ±
4.2-fold induction and is activated by LG335 at the
same concentration (EC50 value is 338 nM) but only at
a fold induction of 6.0 ± 2.3. Figure 1B shows the fold
induction at different concentrations of LG335 with
QCIMFI and RXRwt. QCIMFI is activated at lower con-
centrations of LG335 and has much higher fold
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inductions than RXRwt. These results led to the devel-
opment of a molecular switch using the QCIMFI variant
and the ligand LG335.
As previously mentioned, one criterion for an effective
molecular switch system is for the molecular switch to
be target specific, without interference with endogenous
pathways. To address this issue, the DBD of the receptor
was switched from a RXR DBD to a Gal4 DBD. Gal4 is
a yeast transcription factor that consists of two domains,
a DNA binding domain and an activation domain. The
DBD binds to four multiple repeats of a 17-mer DNA
sequence called Gal4 RE [30]. This sequence, unique to
yeast, provides specificity to a target promoter region
containing Gal4 RE, and should not bind to endogenous
mammalian DNA sequences. Thus, the fusion of the
Gal4 DBD and the LBD of the RXR variant
(GRQCIMFI) creates a new transcription factor involved
in the molecular switch system addressed in this paper.
In an effort to eventually introduce stable expression,
GRQCIMFI was cloned into a retroviral expression vec-
tor, pMSCV, and the vector was renamed
pMSCVGRQCIMFI. In this vector GRQCIMFI is consti-
tutively expressed under the control of enhancers and a
promoter in the long terminal repeat (LTR) region.
Upon binding of LG335, GRQCIMFI can bind to a sepa-
rate plasmid, p17*4TataLuc, containing four tandem
Figure 1 Dose Response Curves for RXR Variants. (A) Dose response curves for the activation of wild-type RXR DBD and LDB (RXRwt) and
RXR variant Q275C;I310M;F313I with RXR DBD (QCIMFI) in response to 9cRA and LG335. Activity is measured in relative light units (RLU) derived
from the measurement of luciferase activity and normalization against a b-galactosidase internal standard. Basal activity is around 20 RLUs. (B)
Fold inductions of RXRwt and QCIMFI in the presence of various LG335 concentrations.
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Gal4 RE located upstream from a minimal thymidine
kinase promoter (Ptk), which induces expression of the
Renilla luciferase gene (Figure 2A).
To assess the activation of our molecular switch sys-
tem, pMSCVGRQCIMFI and p17*4TataLuc were
cotransfected into HEK293T cells at a 1:2 molar ratio
respectively, and tested with a range of ligand concen-
trations. As shown in Figure 2B, the two-component
system induces expression of luciferase at 100 nM
LG335 (EC50 value is 11 nM) leading to a 6.3 ± 1.7-fold
induction ratio of luciferase activity, whereas activation
with 9cRA only occurs at the highest concentration of
ligand, 10 μM 9cRA (EC50 value is above 10 μM).
To further test the selectivity of GRQCIMFI to the
Gal4 RE and LG335, GRQCIMFI was tested with an
endogenous RE and compounds known to activate RXR.
A combination of plasmids containing GRQCIMFI or
RXRwt (pMSCVGRQCIMFI or pCMXRXR) along with
reporter plasmid (p17*4TataLuc or pLuc_CRBPII) were
cotransfected into HEK293T cells at a 1:2 molar ratio
respectively with no ligand and with 1 μM ligand
(LG335, 9cRA, and all-trans retinoic acid (atRA)). The
plasmid pCMXRXR contains full length RXRwt under
the control of a cytomegalovirus (CMV) promoter, and
the pLuc_CRBPII plasmid contains RXR response ele-
ments controlling expression of firefly luciferase. As
shown in Figure 3, the cotransfection of pMSCVGR
QCIMFI and p17*4TataLuc results in a 4.5 ± 1.1-fold
induction in the presence of 1 μM LG335, only a 1.2 ±
0.3-fold induction is observed with 9cRA, and a 2.1 ±
0.5-fold induction with atRA. As expected, activation
does not occur when pMSCVGRQCIMFI is cotrans-
fected with pLuc_CRBPII due to the fact that the Gal4
DBD does not bind to the RXR RE. Conversely, when
pCMXRXR and pLuc_CRBPII plasmids are cotrans-
fected, the highest activation occurs in the presence of
the natural ligands, 9cRA and atRA, with fold inductions
of 10.1 ± 3.0 and 5.7 ± 1.0, respectively. When
pCMXRXR is cotransfected with p17*4TataLuc, minimal
activation occurs since the RXR DBD does not recog-
nize the Gal4 RE. The lack of activation of the molecu-
lar switch with endogenous RE and ligands shows that
the engineered transcription factor has specificity to its
target enhancer region and is orthogonal to the ligand,
LG335.
Ligand time course
The time course of the ligand LG335 was assessed to
determine the effect when ligand is continuously present
in the cells 8 hours after transfection, as well as the
removal of ligand 32 hours after transfection. Experi-
mental results from several data sets were averaged (Fig-
ure 4), where HEK293T cells were cotransfected with
pMSCVGRQCIMFI and p17*4TataLuc at a 1:2 molar
ratio. All the cells received 100 nM LG335 eight hours
after transfection; however, subsets of cells were washed
with growth media 32 hours after transfection to
remove LG335. As shown in Figure 4, when ligand is
not removed from the medium, luciferase activity is
detected within 24 hrs and activation increases 56 hours
after transfection. A slight decrease in luciferase activity
is observed after 56 hours, which could be due in part
to the viability of the cells. However, when ligand is
removed 32 hours after transfection, an immediate
decrease in luciferase activity is observed at the next
time point. These results show LG335 can induce trans-
gene activation within 24 hours of adding ligand, and
the ligand activation increases for about 56 hours after
induction.
Characterization of the one-component molecular switch
system
As shown in the previous sections, the two-component
system is capable of regulating gene expression; how-
ever, cotransfecting two plasmids is less desirable than
transfecting a single plasmid. Any given cell needs both
plasmids for the molecular switch to function, causing
possible complications when administering this system
in therapeutic applications. To make the system more
versatile for stable expression in cell culture, all parts of
the four kilobase sequence of the two-component sys-
tem were cloned into the pMSCV vector, called
GRQCIMFIGFP. In this vector, GRQCIMFI is constitu-
tively expressed and in the presence of ligand induces
expression of the enhanced green fluorescent protein
(eGFP) (Figure 5A). The reporter gene was switched
from luciferase to eGFP, since eGFP has the advantage
of visualization of protein expression.
To evaluate the one-component system, GRQCIM-
FIGFP was transiently transfected into HEK293T cells
with no ligand, 10 nM and 10 μM LG335. These results
were compared to a control plasmid pMSCVIRESGFP,
which constitutively expresses eGFP and contains an
internal ribosomal entry site (IRES) prior to the eGFP
DNA sequence (results not shown), to evaluate transfec-
tion efficiency. IRES is a DNA sequence that initiates
translation of RNA by recruiting ribosomal subunits to
a site on the RNA other than the 5’ end [31,32]. Due to
the continuous expression of the eGFP in the
pMSCVIRESGFP plasmid, the protein expression levels
are expected to be higher than that of our molecular
switch. The transfection efficiency with the IRESGFP
plasmid is approximately 60% (data not shown). The
results in Figure 5B show that without ligand, basal GFP
expression is observed where approximately 7% of the
cells are dimly fluorescent. Upon the addition of 10 nM
LG335 (Figure 5C) the intensity of the fluorescence
increases and approximately 10% exhibit GFP
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Figure 2 Two-Component Molecular Switch System. (A) Schematic diagram of a two-component molecular switch system. The engineered
nuclear receptor GRQCIMFI (Gal4 DBD-RXR variant QCIMFI LBD) is constitutively expressed from plasmid pMSCVGRQCIMFI; and in the presence
of ligand LG335, GRQCIMFI will bind to the Gal4 response elements (Gal4 RE). Gal4 RE is a 17-mer sequence that is repeated four times and is in
front of the thymdine kinase promoter (Ptk). The Gal4 RE as well as the target gene is in the plasmid p17*4TataLuc. When GRQCIMFI is bound to
Gal4 RE the transcription machinery is recruited and the target gene, Renilla luciferase, is expressed. Therefore, the expression of the target gene
is ligand-activated. (B) Luciferase assay of GRQCIMFI in the presence of LG335 (-◆-) or 9cRA (—■—). Basal activity is around 2000 RLUs.
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expression. In the presence of 10 μM LG335 the expres-
sion of GFP is detected in about 30% of HEK293T cells
(Figure 5D). In comparing the one-component to the
two-component system, we find that both systems can
be used as a reliable molecular switch. However, the
one-component system may be more suitable because of
the increased efficiency in cellular delivery.
Characterizing integration and stable expression of the
molecular switch in NIH3T3 cell line
After characterizing transient expression of the one-
component system, the next step was to analyze stable
expression of the molecular switch. One way to intro-
duce stable expression of the molecular switch system is
to infect cells using a retrovirus. Retroviral transductions
allow the molecular switch’s DNA to be integrated into
the genome. Stable integration of the transgene allows
for the testing of target gene expression over an
extended period of time and after multiple cell passages.
To generate retrovirus, the ecotropic retroviral vector,
GRQCIMFIGFP, was transiently transfected into the
EcoPack 293 packaging cell line and infectious retroviral
particles were collected and transduced into NIH3T3
cells. The multiplicity of infection used to infect cells
was 0.44. These cells were then analyzed for integration
of the virus into the cellular genome. To determine inte-
gration of the molecular switch sequence, a genomic
extraction of NIH3T3 cells was collected and analyzed
by nesting PCR. As shown in Figure 6A, PCR experi-
ments were performed with primers that annealed to
separate regions of the four kilobase one-component
system. Primer sets “1” and “2” were used in PCRs with
genomic DNA, and secondary PCRs were done with pri-
mer sets “1’ “ and “2’ “ to eliminate non-specific binding
to genomic DNA sequences. As a positive control, these
experiments were performed alongside plasmid DNA.
Figure 6B shows the PCR fragments from the genomic
DNA are the same size as predicted, suggesting that cel-
lular integration occurs without transgene rearrange-
ment. Genomic PCR fragments were also confirmed by
sequencing. These results indicated that administrating
this system through a retrovirus successfully integrated
the molecular switch sequence into target cells.
To assess the regulation of the stable molecular switch
system, NIH3T3 cells transduced with GRQCIMFIGFP
were grown in media with no LG335 or 10 μM LG335
for 24 hours. These results show no GFP fluorescence is
observed when no ligand is applied (Figure 6C), whereas
Figure 3 GRQCIMFI Orthogonality. Luciferase assays in the presence of 1 μM different ligands: LG335, 9cRA, or atRA. Constitutively expressed
nuclear receptor, GRQCIMFI or RXRwt were cotransfected with p17*4TataLuc or pLuc_CRBPII. These plasmids have either Gal4 or RXR response
elements respectively as well as the target gene, luciferase. Fold inductions for this assay are reported and normalized to wells with no ligand.
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34% of the cells are fluorescent upon the addition of 10
μM LG335 (Figure 6D), further confirming this system
as a useful tool for controlling gene expression.
Discussion
One of the most widely used methods to control gene
expression is molecular switch systems. These systems
are composed of a transcription factor that interacts
with a small molecule and an unnatural promoter [18],
which produce relatively high activation levels. These
systems are promising for research as well as clinical
applications because they have been used for analyzing
gene function in both cell culture as well as animal
models [33,34].
As discussed previously, three successful ligand-depen-
dent molecular switch systems have been used for var-
ious cellular studies; however, these systems contain
certain limitations for in vivo applications. For example,
the tetracycline-dependent system is composed of pro-
teins from bacteria that may induce an immune
response [12,13]. The GeneSwitch® system uses RU486,
a progesterone receptor (PR) antagonist and female con-
traceptive drug [35]; long term usage of this drug could
lead to significant side effects, making this system
difficult for animal studies [34]. The EcR-responsive sys-
tem requires the heterodimerization of EcR with RXR.
RXR is a reluctant dimer partner of EcR and over
expression of RXR leads to potential interference in a
plethora of metabolic pathways [36-38].
To address some of these disadvantages, a molecular
switch system was developed using an orthogonal
ligand/NR pair: LG335 and GRQCIMFI. This ligand/
receptor pair is a sensitive switch showing activation of
transgene at LG335 levels as low as 100 nM and activa-
tion was only observed with the wild-type ligand at very
high concentrations. GRQCIMFI is constitutively
expressed, and in the presence of ligand can activate
expression of a target gene 6-fold. GRQCIMFI displays
orthogonal behavior with LG335 and binds specific
DNA sequences called Gal4 RE, exhibiting tight control
over the target gene. Activation occurs only when
pMSCVGRQCIMFI and p17*4TataLuc were cotrans-
fected and 100 nM LG335 was added to the cells. No
activation above basal activity occurred when
pMSCVGRQCIMFI was transfected under different con-
ditions. Wild type RXR shows high activation with the
natural ligand, 9cRA; activation was also observed with
LG335, but only at high concentrations. The ligand
Figure 4 Ligand Time Course. HEK293T cells were transfected with pMSCVGRQCIMFI and p17*4TataLuc and 8 hours after transfection 100 nM
of LG335 was added to cells. Cells were harvested every 8 hours for the ligand time course. Grey bars represent the addition of LG335 8 hours
after transfection. The black bars represent the addition of LG335 8 hours after transfection and the removal of ligand 32 hours after. The white
bars represent cells transfected with plasmid, but no ligand was added.
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Figure 5 One-Component System. (A) Schematic diagram of one-component molecular switch system. All components of the molecular
switch system were cloned into a pMSCV vector with eGFP as the target gene called GRQCIMFIGFP. (B, C, and D) HEK293T cells were
transfected with GRQCIMFIGFP and (B) no ligand (C) 10 nM, or (D) 10 μM of LG335. Pictures were taken 40 hours after transfection and 32 hours
after adding ligand.
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LG335 is a derivative of the FDA clinically approved
drug bexarotene, but only bexarotene has biological
relevance and can activate RXR [39,40].
As stated in the introduction, there are certain criteria
for a molecular switch system. Some of these criteria
include the turning on and off of transgene expression
upon the addition of ligand. This system shows activa-
tion with two different reporters when LG335 was
added; however, slight basal levels occur with both
reporters when no ligand had been added. The ligand
should be target specific and not interfere with endo-
genous pathways. We have shown that GRQCIMFI does
not bind to RXR RE. Slight activation is observed with
RXRwt but only at the highest concentration of ligand.
It has also been shown that 10 μM 9cRA actives
GRQCIMFI, but this concentration is much higher than
cellular levels; therefore, it is expected that 9cRA will
not activate this molecular switch. Lastly, the ligand
should show rapid reversible transgene activation. This
molecular switch system shows rapid induction, where
activation levels are observed 16 hours after the addition
of ligand. However, the removal of LG335 shows a slow
and steady decrease in transgene expression. Possible
improvements in this system can be achieved by adding
Figure 6 Integration of GRQCIMFIGFP. Genomic DNA was extracted from NIH3T3 cells transduced with GRQCIMFIGFP virus. PCR on genomic
DNA shows that retroviral genes were integrated into the genome of cells. (A) The retroviral construct and the places where the different
primers bind within the retrovirus construct. (B) An electrophoresis gel of the PCR product from genomic DNA (lanes 2 and 5) and plasmid DNA
(lanes 3 and 4). Using primers 1f and 1r and then 1f’ and 1r’ to clone out a 1029 bp band (lanes 2 and 3). Primers 2f and 2r and then 2f’ and 2r’
were used to clone out a 1650 bp band (lanes 4 and 5). Lane is an l kb molecular weight marker. Figure (C and D) are pictures of NIH3T3 cells
transduced with GRQCIMFIGFP with (C) no ligand and (D) 10 μM LG335.
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a transactivation domain to increase activation levels
[41], adding an insulator sequence to overcome promo-
ter position effect [42], or adding an IRES sequence to
increase the translation efficiency [43].
Initially, the molecular switch system was a two-com-
ponent system with GRQCIMFI in one plasmid and the
artificial promoter and target transgene in another plas-
mid. Then the system was combined into a one-compo-
nent system containing all parts of the switch in one
plasmid. While both systems were shown to regulate
target gene expression proficiently, a one-component
system provides versatility and efficiency by decreasing
the amount of exogenous DNA required for the system
to function [44]. The one-component system can be
introduced virally into NIH3T3 cells and can stably
express proteins. Integration of the molecular switch
system into the genome is one way to introduce stable
expression into a cellular environment while also pas-
sing the system’s DNA material onto newly regenerated
cells.
Conclusions
Our data reveals a promising molecular switch system
that drives controlled expression of two different repor-
ter genes, luciferase and GFP, with high sensitivity and
comparable induction ratios to other molecular switch
systems. This system can be used in cell culture to
assess gene expression of an array of target genes.
Methods
Ligands
9-cis-retinoic acid (MW 304.44 g/mol) and all-trans-
retinoic acid (MW 300.44 g/mol) were purchased (ICN
Biomedicals, USA). LG335 was synthesized in our lab
[45,46].
Plasmids
The pMSCVGRQCIMFI plasmid was constructed via
PCR amplification of the Gal4 DBD and RXR LBD var-
iant from the pGBDRXRQCIMFI plasmid using primers
and BglII restriction sites. p17*4TataRluc was con-
structed from p17*4TataFLuc (a gift from Dr Sofia Tsai,
Baylor College, Houston, TX) [47,48] by replacing the
firefly luciferase with Renilla luciferase. The Renilla luci-
ferase was cloned from pHRL (Clontech, USA) with
NotI and SacII restriction sites. The internal standard
plasmid pCMX-bGAL constitutively expresses b-galacto-
sidase under control of the CMV promoter. The plas-
mids pCMXRXRwt and pCMXQCIMFI have been
previously described [29]. The pLuc_CRPBII was made
by site-directed mutagenesis from pLucMCS (Stratagene,
USA). Site-directed primers were designed to incorpo-
rate a CRBPII response element in the multiple cloning
site (MCS).
Cell culture conditions
All cell types were maintained at 37°C in humidified air
with 5% CO2. NIH3T3 (ATCC, USA) and HEK293T
(ATCC, USA) cells were cultured in Dulbecco’s Modi-
fied Eagle Medium (DMEM, Mediatech Inc, USA) sup-
plemented with 10% calf bovine serum (CBS, Thermo
Scientific, USA) and 1% penicillin/streptomycin (PS,
VWR, USA).
Mammalian luciferase assays
Transfections of HEK293T cells were performed in 48-
well plates with Lipofectamine 2000 (Invitrogen, USA)
as the cationic lipid as recommended by the manufac-
turer. Briefly, 20 ng of pMSCVGRQCIMFI expression
plasmid, 40 ng of p17*4TataLuc reporter plasmid, and
40 ng of pCMX-bGAL expression plasmid (used as an
internal standard) were mixed with 0.3 μL of lipofecta-
mine 2000 in 40 μL of Opti-Mem (Invitrogen, USA)
reduced serum media per transfected well. After 30-60
minutes an additional 160 μL of Opti-Mem was added
and the 200 μL mixture was added to a well previously
washed with 250 μL of Opti-Mem. After 8 hours of
transfection the wells were aspirated and ligands diluted
in growth media were added to the wells. Cells were
harvested after 36-40 hours and assayed for luciferase
and b-galactosidase activities. All data points represent
the mean of triplicate experiments normalized against
b-galactosidase activity. Error bars represent the stan-
dard deviation. All experiments were carried out in tri-
plicate sets.
Ligand time course
The transfection for this assay was done the same as
stated above in the luciferase assay. However, cells were
harvested every 8 hours for luciferase and b-galactosi-
dase activity. Two experimental data sets were taken
and each set was divided by the maximum RLUs and
multiplied by 100 to receive the percent maximal RLUs.
Then the average and standard deviation of both sets
were calculated.
Mammalian GFP analysis
Transfections of HEK293T cells were performed in 12-
well plates with Lipofectamine 2000 cationic lipid as
recommended by the manufacturer. Briefly, 1.6 μg of
pMSCVGRQCIMFIGFP reporter plasmid was mixed
with 4 μL of lipofectamine 2000 in 200 μL of Opti-Mem
reduced serum media per transfected well. After 30-60
minutes an additional 1600 μL of Opti-Mem was added
and the 2 mL mixture was added to a well previously
washed with 2 mL of Opti-Mem. After 8 hours of trans-
fection the wells were aspirated and ligands diluted in
growth media were added to the wells. Images of trans-
fected cells were taken using a 40× objective on a Zeiss
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LSM microscope. To obtain the percentage of fluores-
cent cells, the number of fluorescent cells counted was
divided by the total number of cells counted multiplied
100. Images were processed on Adobe Photoshop to
convert green fluorescence to gray-scale. All experi-
ments were carried out in triplicate sets.
Retrovirus
16 μg of pMSCVGRQCIMFIGFP was transiently trans-
fected into EcoPack-293T cells (Clontech, USA) with 20
μL of lipofectamine 2000 and 6 mL of Opti-Mem. After
eight hours, the media was changed to 7 mL of growth
media. Collected viral particles in media on cells every
10-15 hours and filtered with a 0.45 μm syringe filter
(Pall Corporation, USA). Transduction was done with 1
mL of media containing virus. Media was incubated
with 80 μg/mL of chondroitin 6-sulfate sodium salt
from shark cartilage (CSC, Sigma Aldrich, USA) for 10
minutes, and then with 80 μg/mL of polybrene (PB,
Millipore Corporation, USA) for 10 minutes. Add media
to 6-well plate of NIH3T3 cells with 8 μg/mL of poly-
brene. To obtain the percentage of fluorescent cells, the
number of fluorescent cells counted was divided by the
total number of cells counted multiplied by 100. Images
of transduced cells were taken using a 40× objective on
a Zeiss LSM microscope. To invert the images to gray
scale, Adobe Photoshop was used. All experiments were
carried out in duplicate sets.
Genomic PCRs
Genomic DNA was collected using the DNeasy kits
(Qiagen, USA). To clone the 1029 bp DNA sequence
from genomic DNA, a primary PCR was performed
using the following primers: 1f, CCT TGA CAT GAT
TTT GAA AAT GG; 1r, GCC GCC TAA GTC ATT
TGG TG. Then a secondary PCR was performed with
the following primers: 1f’, ATT CTT TAC AGG ATA
TAA AAG CAT TGT TAA CAG GAT; 1r’, CGC CTC
CAG CAT CTC CAT AAG G. To clone out the 1650
bp DNA sequence, a primary PCR was done with the
following primers: 2f, GAG GTG GAG TCG ACC AGC
AG; 2r, TTA CTT GTA CAG CTC GTC CAT GC. A
secondary PCR was done with the following primers: 2f’,
CGC CAA CGA GGA CAT GCC G; 2r’, CGA GAG
TGA TCC CGG CGG C. Pfu polymerase (Stratagene,
USA) was used. The PCR fragments were analyzed on a
1.2% agarose gel.
Abbreviations
NR: nuclear receptors; RXR: retinoid × receptor; DBD: DNA binding domain;
LBD: ligand binding domain; RE: response element; 9cRA: 9-cis-retinoic acid;
atRA: all-trans retinoic acid; eGFP: enhanced green fluorescent protein; PR:
progesterone receptor; RU486: mifepristone; Tet: tetracycline; dox:
doxycycline; EcR: ecdysone receptor; wt: wild type; CMV: cytomegalovirus.
Acknowledgements
We thank Dr. Sofia Tsai for the p17*4TataFLuc plasmid. We also thank Dr.
Joseph LeDoux and Dr. Christoph Fahrni and their labs, especially Reagan
McRae, for training and materials. This work was funded by NIH grant
1R21HL081165.
Author details
1School of Chemistry and Biochemistry, Georgia Institute of Technology, 901
Atlantic Drive, Atlanta, GA 30332, USA. 2Pharmacokinetics and ADME group,
Baxter Healthcare, One Baxter Parkway Deerfield, IL 60015-4625, USA. 3Aflac
Cancer Center and Blood Disorders Services, Department of Pediatrics,
Emory University School of Medicine, Atlanta, GA 30322, USA.
Authors’ contributions
JLT conceived and designed the study, carried out all the collection, analysis
and interpretation of data, and drafted the manuscript. PR contributed to
the design of the study and the technical direction of the experiments. THS,
DFD, and BA contributed to the conception and design of the study, and
the preparation of the manuscript. All authors read and approved the final
manuscript.
Received: 9 October 2009
Accepted: 18 February 2010 Published: 18 February 2010
References
1. Pollock R, Clackson T: Dimerizer-regulated gene expression. Curr Opin
Biotechnol 2002, 13(5):459-467.
2. Clackson T: Controlling mammalian gene expression with small
molecules. Curr Opin Chem Biol 1997, 1(2):210-218.
3. Wang YL, Omalley BW, Tsai SY: A regulatory system for gene-transfer. Proc
Natl Acad Sci USA 1994, 91(17):8180-8184.
4. Gossen M, Bujard H: Tight control of gene-expression in mammalian-cells
by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992,
89(12):5547-5551.
5. No D, Yao TP, Evans RM: Ecdysone-inducible gene expression in
mammalian cells and transgenic mice. Proc Natl Acad Sci USA 1996,
93(8):3346-3351.
6. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, Omalley BW: The
mechanism of RU486 antagonism is dependent on the conformation of
the carboxy-terminal tail of the human progesterone-receptor. Cell 1992,
69(4):703-713.
7. Wang Y, Xu J, Pierson T, Omalley BW, Tsai SY: Positive and negative
regulation of gene expression in eukaryotic cells with an inducible
transcriptional regulator. Gene Therapy 1997, 4(5):432-441.
8. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O’Malley BW: Adenovirus-
mediated regulable target gene expression in vivo. Proc Natl Acad Sci
USA 1999, 96(2):355-360.
9. Nordstrom JL: The antiprogestin-dependent GeneSwitch (R) system for
regulated gene therapy. 2003: Elsevier Science Inc 2003, 1085-1094.
10. Salucci V, Scarito A, Aurisicchio L, Lamartina S, Nicolaus G, Giampaoli S,
Gonzalez-Paz O, Toniatti C, Bujard H, Hillen W, Ciliberto G, Palombo F: Tight
control of gene expression by a helper-dependent adenovirus vector
carrying the rtTA2(s)-M2 tetracycline transactivator and repressor
system. Gene Therapy 2002, 9(21):1415-1421.
11. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA: Tetracycline-controlled
transcriptional regulation systems: advances and application in
transgenic animal modeling. Semin Cell Dev Biol 2002, 13(2):121-128.
12. Favre D, Blouin V, Provost N, Spisek R, Porrot F, Bohl D, Marme F, Cherel Y,
Salvetti A, Hurtrel B, Heard JM, Riviere Y, Moullier P: Lack of an immune
response against the tetracycline-dependent transactivator correlates
with long-term doxycycline-regulated transgene expression in
nonhuman primates after intramuscular injection of recombinant
adeno-associated virus. J Virol 2002, 76(22):11605-11611.
13. Latta-Mahieu M, Rolland M, Caillet C, Wang MP, Kennel P, Mahfouz I,
Loquet I, Dedieu JF, Mahfoudi A, Trannoy E, Thuillier V: Gene transfer of a
chimeric trans-activator is immunogenic and results in short-lived
transgene expression. Hum Gene Ther 2002, 13(13):1611-1620.
14. No D, Yao TP, Evans RM: Ecdysone-inducible gene expression in
mammalian cells and transgenic mice. Proc Natl Acad Sci USA 1996,
93(8):3346-3351.
Taylor et al. BMC Biotechnology 2010, 10:15
http://www.biomedcentral.com/1472-6750/10/15
Page 11 of 12
15. Karns LR, Kisielewski A, Gulding KM, Seraj JM, Theodorescu D: Manipulation
of gene expression by an ecdysone-inducible gene switch in tumor
xenografts. BMC Biotechnol 2001, 1:11.
16. Palli SR, Kapitskaya MZ, Kumar MB, Cress DE: Improved ecdysone receptor-
based inducible gene regulation system. Eur J Biochem 2003,
270(6):1308-1315.
17. Subbarayan V, Mark M, Messadeq N, Rustin P, Chambon P, Kastner P:
RXRalpha overexpression in cardiomyocytes causes dilated
cardiomyopathy but fails to rescue myocardial hypoplasia in RXRalpha-
null fetuses. J Clin Invest 2000, 105(3):387-394.
18. Toniatti C, Bujard H, Cortese R, Ciliberto G: Gene therapy progress and
prospects: transcription regulatory systems. Gene Therapy 2004,
11(8):649-657.
19. Germain P, Staels B, Dacquet C, Spedding M, Laudet V: Overview of
nomenclature of nuclear receptors. Pharmacol Rev 2006, 58(4):685-704.
20. Sonoda J, Pei LM, Evans RM: Nuclear receptors: Decoding metabolic
disease. FEBS Lett 2008, 582(1):2-9.
21. Pollock R, Giel M, Linher K, Clackson T: Regulation of endogenous gene
expression with a small-molecule dimerizer. Nat Biotechnol 2002,
20(7):729-733.
22. Bishop A, Buzko O, Heyeck-Dumas S, Jung I, Kraybill B, Liu Y, Shah K,
Ulrich S, Witucki L, Yang F, Zhang C, Shokat KM: Unnatural ligands for
engineered proteins: New tools for chemical genetics. Annu Rev Biophys
Biomolec Struct 2000, 29:577-606.
23. Boehm MF, McClurg MR, Pathirana C, Mangelsdorf D, White SK, Hebert J,
Winn D, Goldman ME, Heyman RA: Synthesis of high specific activity [3H]-
9-cis-retinoic acid and its application for identifying retinoids with
unusual binding properties. J Med Chem 1994, 37(3):408-414.
24. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM,
Goldman ME, Heyman RA: Synthesis and structure-activity relationships
of novel retinoid × receptor-selective retinoids. J Med Chem 1994,
37(18):2930-2941.
25. Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors.
Cell 1995, 83(6):841-850.
26. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM: Nuclear receptor that
identifies a novel retinoic acid response pathway. Nature 1990,
345(6272):224-229.
27. Shulman AI, Mangelsdorf DJ: Mechanisms of disease: Retinoid × receptor
heterodimers in the metabolic syndrome. N Engl J Med 2005,
353(6):604-615.
28. Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong ES, Evans RM:
A direct repeat in the cellular retinol-binding protein type-II gene
confers differential regulation by RXR and RAR. Cell 1991, 66(3):555-561.
29. Doyle DF, Braasch DA, Jackson LK, Weiss HE, Boehm MF, Mangelsdorf DJ,
Corey DR: Engineering orthogonal ligand-receptor pairs from “near
drugs”. Journal of the American Chemical Society 2001, 123(46):11367-11371.
30. Lohr D, Venkov P, Zlatanova J: Transcriptional regulation in the yeast gal
gene family - A complex genetic network. Faseb J 1995, 9(9):777-787.
31. Kieft JS: Viral IRES RNA structures and ribosome interactions. Trends
BiochemSci 2008, 33(6):274-283.
32. Pfingsten JS, Kieft JS: RNA structure-based ribosome recruitment: Lessons
from the Dicistroviridae intergenic region IRESes. RNA-Publ RNA Soc 2008,
14(7):1255-1263.
33. Mulligan RC: The basic science of gene therapy. Science 1993,
260(5110):926-932.
34. Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, Soffer EB,
Mondkar S, King GD, Hu J, Sciascia SA, Candolfi M, Greengold DS,
Lowenstein PR, Castro MG: Regulatable gene expression systems for gene
therapy applications: Progress and future challenges. Mol Ther 2005,
12(2):189-211.
35. Sarkar NN: Mifepristone: bioavailability, pharmacokinetics and use-
effectiveness. Eur J Obstet Gynecol Reprod Biol 2002, 101(2):113-120.
36. Thomas HE, Stunnenberg HG, Stewart AF: Heterodimerization of the
drosophila ecdysone receptor with retinoid × receptor and ultraspirale.
Nature 1993, 362(6419):471-475.
37. Yao TP, Forman BM, Jiang ZY, Cherbas L, Chen JD, McKeown M, Cherbas P,
Evans RM: Functional ecdysone receptor is the product of ECR and
ultraspiracle genes. Nature 1993, 366(6454):476-479.
38. Yao TP, Segraves WA, Oro AE, McKeown M, Evans RM: Drosophila
ultraspiracle modulates ecdysone receptor function via heterodimer
formation. Cell 1992, 71(1):63-72.
39. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM,
Goldman ME, Heyman RA: Synthesis and structure activity relationships
of novel retinoid × receptor selective retinoids. J Med Chem 1994,
37(18):2930-2941.
40. Boehm MF, Zhang L, Zhi L, McClurg MR, Berger E, Wagoner M, Mais DE,
Suto CM, Davies PJA, Heyman RA, Nadzan AM: Design and synthesis of
potent retinoid × receptor selective ligands that induce apoptosis in
leukemia-cells. J Med Chem 1995, 38(16):3146-3155.
41. Ingles CJ, Shales M, Cress WD, Triezenberg SJ, Greenblatt J: Reduced
binding of TFIID to transcriptionally compromised mutants of VP16.
Nature 1991, 351(6327):588-590.
42. Osti D, Marras E, Ceriani I, Grassini G, Rubino T, Vigano D, Parolaro D,
Perletti G: Comparative analysis of molecular strategies attenuating
positional effects in lentiviral vectors carrying multiple genes. J Virol
Methods 2006, 136(1-2):93-101.
43. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P: A versatile tool
for conditional gene expression and knockdown. Nat Methods 2006,
3(2):109-116.
44. Lattime EC: Retroviral Vector Design for Cancer Gene Therapy. Gene
Therapy of Cancer San Diego: Academic Press, 2 2002, 3-23.
45. Schwimmer LJ, Rohatgi P, Azizi B, Seley KL, Doyle DF: Creation and
discovery of ligand-receptor pairs for transcriptional control with small
molecules. Proc Natl Acad Sci USA 2004, 101(41):14707-14712.
46. Schwimmer LJ: Engineering ligand-receptor pairs for small molecule
control of transcription. Atlanta: Georgia Institute of Technology 2005.
47. Wang Y, O’Malley BW Jr, Tsai SY, O’Malley BW: A regulatory system for use
in gene transfer. Proc Natl Acad Sci USA 1994, 91(17):8180-8184.
48. Wang Y, Xu J, Pierson T, O’Malley BW, Tsai SY: Positive and negative
regulation of gene expression in eukaryotic cells with an inducible
transcriptional regulator. Gene Ther 1997, 4(5):432-441.
doi:10.1186/1472-6750-10-15
Cite this article as: Taylor et al.: Characterization of a molecular switch
system that regulates gene expression in mammalian cells through a
small molecule. BMC Biotechnology 2010 10:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Taylor et al. BMC Biotechnology 2010, 10:15
http://www.biomedcentral.com/1472-6750/10/15
Page 12 of 12
